BUZZ-Oncolytics Biotech Inc: Lead cancer drug gets orphan drug status
** Drug developer's U.S.-listed shares up 6.21 pct at $0.75 premarket
** Company's lead pancreatic cancer drug, Reolysin, gets orphan drug status from European health regulator
** Orphan status, granted to drugs developed to treat rare diseases, gives developer several incentives including seven-year U.S. marketing exclusivity
** Up to Tuesday's close, stock gained 32 pct this year
© Thomson Reuters 2017 All rights reserved.